BiTEs: bispecific antibody constructs with unique anti-tumor activity
Abstract
Bispecific T-cell engager molecules (BiTEs) constitute a class of bispecific single-chain antibodies for the polyclonal activation and redirection of cytotoxic T cells against pathogenic target cells. BiTEs combine a unique set of properties that have not yet been reported for any other kind of bispecific antibody construct, namely extraordinary potency and efficacy against target cells at low T-cell numbers without the need for T-cell co-stimulation. Here we review novel insights into the mechanism of BiTE action, which help to explain the unique features of BiTEs, as well as data from various animal models demonstrating the outstanding therapeutic potential of BiTEs for the treatment of malignant diseases.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The small size of BiTEs might be responsible for their high efficiency by leading to the active displacement of negative regulatory proteins from the forming synapse.
“The small size (60 kDa) of BiTEs, which ensures close proximity of T cells and target cell membranes, might therefore be responsible for their high efficiency by leading to the active displacement of negative regulatory proteins from the forming synapse, as demonstrated in the case of CD45. 47”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [47]
In some cases, up to 18 fM of BiTEs was shown to be enough to induce in vitro cell lysis.
“In some cases, up to 18 fM was shown to be enough to induce in vitro cell lysis”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [47]
BiTEs have a small size of 60 kDa that ensures close proximity of T cells and target cell membranes.
“The small size (60 kDa) of BiTEs, which ensures close proximity of T cells and target cell membranes, might therefore be responsible for their high efficiency by leading to the active displacement of negative regulatory proteins from the forming synapse, as demonstrated in the case of CD45. 47”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [47]
The citation lists haven’t been fetched yet
References 58 · Cited by 260
- Authors
- Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A.
- Corresponding author
- Baeuerle, Patrick A.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 10
- Issue
- 18
- Pages
- 1237-1244
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2072449326
- Cited by
- 260
- References
- 58
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 19 · 2023: 21 · 2022: 11 · 2021: 20 · 2020: 15 · 2019: 16 · 2018: 15 · 2017: 16 · 2016: 12 · 2015: 14 · 2014: 13 · 2013: 14 · 2012: 17
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- bispecific T-cell engagers, bispecific antibodies, single-chain antibody, T cell redirection, cytotoxic T lymphocytes, T cell activation, T cell costimulation, anticancer activity, cancer immunotherapy, mechanism of action, animal models of cancer
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Humans, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Antibodies, Bispecific
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
